REGENERON PHARMACEUTICALS INC. - COMMON STOCK

738,00

22-ноября-24 16:44:58

15 мин. задержка

Акции

-6,50

-0,87%

Сегодняшний диапазон

737,63 - 751,40

ISIN

N/A

Источник

NASDAQ

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

31 май 2024 01:05:00 Источник Nasdaq GlobeNewswire
Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

31 май 2024 01:00:00 Источник Nasdaq GlobeNewswire
Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO

23 май 2024 17:03:17 Источник Nasdaq GlobeNewswire
Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

20 май 2024 14:15:00 Источник Nasdaq GlobeNewswire
More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

17 май 2024 13:45:49 Источник Nasdaq GlobeNewswire
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

13 май 2024 01:00:00 Источник Nasdaq GlobeNewswire
Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

08 май 2024 06:00:57 Источник Nasdaq GlobeNewswire
Regeneron Announces Investor Conference Presentations

06 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Regeneron Reports First Quarter 2024 Financial and Operating Results

02 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Meaningful Outcomes in Serious Retinal Diseases

29 апр 2024 07:00:18 Источник Nasdaq GlobeNewswire
Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing for Multiple Diseases

25 апр 2024 07:00:00 Источник Nasdaq GlobeNewswire
Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad Range of Solid Tumors and Blood Cancers at ASCO

24 апр 2024 10:05:18 Источник Nasdaq GlobeNewswire
Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Therapy (ASGCT)

22 апр 2024 17:54:01 Источник Nasdaq GlobeNewswire
Linvoseltamab Pivotal Data Presented at AACR Reinforce High Response Rate that Deepens Over Time in Patients with Heavily Pre-Treated Multiple Myeloma

07 апр 2024 16:00:12 Источник Nasdaq GlobeNewswire
Regeneron to Report First Quarter 2024 Financial and Operating Results and Host Conference Call and Webcast on May 2, 2024

01 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Regeneron Provides Update on Biologics License Application for Odronextamab

25 мар 2024 07:00:02 Источник Nasdaq GlobeNewswire
High School Seniors Win $1.8 Million at Regeneron Science Talent Search 2024 for Innovative Scientific Research on Artificial Intelligence, Cancer Metabolism and Mathematical Optimization

12 мар 2024 21:30:22 Источник Nasdaq GlobeNewswire
Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

11 мар 2024 07:00:23 Источник Nasdaq GlobeNewswire
EYLEA® HD (aflibercept) Injection 8 mg Pivotal Data in Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME) Published in The Lancet

08 мар 2024 07:00:26 Источник Nasdaq GlobeNewswire
NetDania - New 12 months High: REGENERON PHARMACEUTICALS INC. - COMMON STOCK

28 фев 2024 09:48:56 Источник NetDania Notify

<<
<
1
2
3
4
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.